Molecular Partners Reports Q3 2025 Financial Results And Clinical Progress, With Dll3-Targeting Radio-Darpin Mp0712 Phase 1 Launch Expected In 2025

RefinitivMeno di 1 minuto di lettura

Molecular Partners AG MOLN:

MOLECULAR PARTNERS REPORTS Q3 2025 FINANCIAL RESULTS AND CLINICAL PROGRESS, WITH DLL3-TARGETING RADIO-DARPIN MP0712 PHASE 1 LAUNCH EXPECTED IN 2025

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Accedi o crea un account gratuito per leggere queste notizie